RE:RE:RE:RE:RE:CIBC Whistler gtmny I understand that it might surprise you but I calculate that at maturity (2021) IVIG and 4050-IPF is only going to bring PLI about 260M$ and 960M$ respectively in operating margins (after prod and sales costs), whereas Plasminogen figure is more in the 4600M$ horizon. For what we know as of now. So Greg is fully justified to spen more time talking about the Plasminogen and 4050-CKD flagships: that's where the bulk of the money is going to be. ;-)
If everything goes as expected I plan to post my new Valuation Update at the end of the day tomorrow. And expect to have time to discuss it ad nauseam on Friday.
Stay tuned...
:-)
FD